First, we successively reported that the expression of some of the pro-angiogenic and/or pro-hypoxic miRNAs studied could actually be affected by IDH mutation and hypoxia in vitro, and then in tumor specimens from patients with glioma that the expression of some pro-angiogenic and/or pro-hypoxic miRNAs could be strongly affected by and correlated with the 2016 WHO classification (IDH1/2 mutation, microvascular proliferation, histoprognostic group according to WHO 2016 classification). This evidence concerns the gene IDH2 and glioma.